In the months leading up to a presidential election, when there is a chance that the White House may change occupants after November, administrations often push their agendas through federal actions, such as regulations and guidance, coming out of the federal departments.
So, while this election year we are not expecting Congress to get much done in terms of actual legislation, we can expect the Biden Administration to ramp up its efforts at pushing things through at the regulatory level.
A good example of this is the proposed rule published late last week that would, in essence, make marijuana legal for medicinal use across the country. The rule, coming out of the Drug Enforcement Administration (DEA) under the Department of Justice (DOJ), proposes that marijuana be changed to a Schedule III substance under the Controlled Substances Act.
Marijuana is currently categorized as a Schedule I substance, defined as a substance for which there is a high potential for abuse, no current medical use, and a lack of accepted safety for use, even under medical supervision.
Last week’s DEA proposed rule follows a determination from the Department of Health and Human Services (HHS) last summer that marijuana in fact does have accepted medical uses, and is less dangerous than other Schedule I drugs, which include heroin and LSD.
This move by the Administration probably triggers more questions than answers, at least with respect to its regulatory challenges. Nearly 40 states have already passed laws that legalize medical use of marijuana, though there is little in the way of state rules on prescriptions, recordkeeping, and other administrative and safety guardrails.
Although the rule would reclassify marijuana, it would still be a controlled substance, which means that federal prosecution is still a risk to anyone who traffics in the drugs or “prescribes” the drugs without the appropriate approvals and processes.
Perhaps just as important as what this proposed rule would do is what the rule would definitely not do. For instance, the proposed rule would not federally legalize marijuana to be grown and sold for recreational use. A total of 24 states allow the sale of recreational cannabis.
As an example of this, the newly proposed rule, if finalized, would not get anyone out of jail who were put there solely for growing or selling marijuana.
Relatedly, the rule would not give the cannabis industry access to credit-card and payment systems.
It is also very unclear what this means for the U.S. drug and healthcare industry at large, as you can well imagine. Could gummies bought at the neighborhood cannabis store now be covered by insurers and bought with your HSAs or FSA?
We are basically at the beginning of what may be a long rulemaking process before the rescheduling actually takes place. However, how long that will take is another question. As you may know, some regulatory changes that have popular support can move quickly from proposed rule to final rule within a year. Other rules can take years. However, we can expect that the Biden Administration will move on this rule quickly.
This may be just the latest in a number of actions that will be taken up this election year by the Biden Administration.
We’ll keep our eyes on it.
Literature is ripe with classic phrases that seem timelessly apropos. For example, take the partial federal government shutdown. For days, the phrase repeated in the
The Medicare Advantage (MA) program has grown significantly over the past two decades, becoming a popular alternative to traditional Medicare fee-for-service (FFS). As of 2023,
Please log in to your account to comment on this article.
Join Beth Wolf, MD, CPC, CCDS, for an in-depth webcast on the FY2025 spinal fusion MS-DRG updates. Discover key changes in DRG classification, understand impacts on documentation and CMI, and learn strategies to ensure compliance.
Join Angela Comfort, DBA, MBA, RHIA, CDIP, CCS, CCS-P, as she presents effective strategies to strengthen collaboration between CDI, coding, and quality departments in acute care hospitals. Angela will also share guidance on implementing cross-departmental meetings, using shared KPIs, and engaging leadership to foster a culture of collaboration. Attendees will gain actionable tools to optimize documentation accuracy, elevate quality metrics, and drive a unified approach to healthcare goals, ultimately enhancing both patient outcomes and organizational performance.
Optimize your outpatient clinical documentation and gain comprehensive knowledge from foundational practices to advanced technologies, ensuring improved patient care and organizational and financial success. This webcast bundle provides a holistic approach to outpatient CDI, empowering you to implement best practices from the ground up and leverage advanced strategies for superior results. You will gain actionable insights to improve documentation quality, patient care, compliance, and financial outcomes.
Enhancing outpatient clinical documentation is crucial for maintaining accuracy, compliance, and proper reimbursement in today’s complex healthcare environment. This webcast, presented by industry expert Angela Comfort, DBA, RHIA, CDIP, CCS, CCS-P, will provide you with actionable strategies to tackle complex challenges in outpatient documentation. You’ll learn how to craft detailed clinical narratives, utilize advanced EHR features, and implement accurate risk adjustment and HCC coding. The session also covers essential regulatory updates to keep your documentation practices compliant. Join us to gain the tools you need to improve documentation quality, support better patient care, and ensure financial integrity.
Dr. Ronald Hirsch provides critical details on the new Medicare Appeal Process for Status Changes for patients whose status changes during their hospital stay. He also delves into other scenarios of hospital patients receiving custodial care or medically unnecessary services where patient notifications may be needed along with the processes necessary to ensure compliance with state and federal guidance.
Healthcare organizations face complex regulatory requirements under the No Surprises Act and Price Transparency rules. These policies mandate extensive fee disclosures across settings, and confusion is widespread—many hospitals remain unaware they must post every contracted rate. Non-compliance could lead to costly penalties, financial loss, and legal risks. Join David M. Glaser Esq. as he shows you how to navigate these regulations effectively.
Protect your facility from unwanted audits! Join Becky Jacobsen, BSN, RN, MBS, CCS-P, CPC, CPEDC, CBCS, CEMC, and take a deep dive into both the CMS and AMA guidelines for reporting post operative pain blocks. You’ll learn how to determine if the nerve block is separately codable with real life examples for better understanding. Becky will also cover how to evaluate whether documentation supports medical necessity, offer recommendations for stronger documentation practices, and provide guidance on educating providers about documentation requirements. She’ll include a discussion of appropriate modifier and diagnosis coding assignment so that you can be confident that your billing of post operative pain blocks is fully supported and compliant.
During this RACmonitor webcast Dr. Ronald Hirsch spotlights the areas of the OIG’s Work Plan and the findings of their most recent audits that impact utilization review, case management, and audit staff. He also provides his common-sense interpretation of the prevailing regulations related to those target issues. You’ll walk away better equipped with strategies to put in place immediately to reduce your risk of paybacks, increased scrutiny, and criminal penalties.
Copyright © 2024 RACmonitor. Powered by MedLearn Media.
Happy National Doctor’s Day! Learn how to get a complimentary webcast on ‘Decoding Social Admissions’ as a token of our heartfelt appreciation! Click here to learn more →
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
